Varicose Veins: Role of Mechanotransduction of Venous Hypertension by Atta, Hussein M.
Hindawi Publishing Corporation
International Journal of Vascular Medicine
Volume 2012, Article ID 538627, 13 pages
doi:10.1155/2012/538627
Review Article
VaricoseVeins: Role of Mechanotransduction of
Venous Hypertension
HusseinM. Atta
Department of Surgery, Faculty of Medicine, Minia University, Misr-Aswan Road, El-Minia 61519, Egypt
Correspondence should be addressed to Hussein M. Atta, attahmh@yahoo.com
Received 30 September 2011; Accepted 13 November 2011
Academic Editor: Marc A. Passman
Copyright © 2012 Hussein M. Atta. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Varicoseveinsaﬀect approximatelyone-thirdoftheadultpopulationandresultinsigniﬁcantpsychological, physical,andﬁnancial
burden. Nevertheless, the molecular pathogenesis of varicose vein formation remains unidentiﬁed. Venous hypertension exerted
on veins of the lower extremity is considered the principal factor in varicose vein formation. The role of mechanotransduction
of the high venous pressure in the pathogenesis of varicose vein formation has not been adequately investigated despite a good
progress in understanding the mechanomolecular mechanisms involved in transduction of high blood pressure in the arterial
wall. Understanding the nature of the mechanical forces, the mechanosensors and mechanotransducers in the vein wall, and the
downstream signaling pathways will provide new molecular targets for the prevention and treatment of varicose veins. This paper
summarizedthecurrentunderstandingofmechano-molecularpathwaysinvolvedintransductionofhemodynamicforcesinduced
by blood pressure and tries to relate this information to setting of venous hypertension in varicose veins.
1.Introduction
Varicose veins are a common venous disease of the lower
extremity which aﬀects more than 30 per cent of the adult
population in Western countries [1–3]. Varicose veins are
elongated, dilated, and tortuous veins. Varicose veins range
in severity from the undesirable appearance of telangiectasia
to large tortuous varicosities with or without associated
swelling, dermatitis, pigmentation, or cutaneous ulcerations
[4]. There is a signiﬁcant ﬁnancial burden of chronic venous
disease thatcomprises varicose veins and their complications
on the health care system, with an estimated $3 billion per
year being spent on the treatment of venous wounds in
the United States [5]. In countries with developed health
care system, the cost of treating advanced venous disease
has accounted for up to 1% to 2% of the total health care
budget [6, 7]. Thus varicose veins pose considerable social
and economic problems.
Varicose veins are characterized by symptoms or signs
produced by venous hypertension as a result of structural
or functional abnormalities of veins. Symptoms may include
aching, heaviness, cramps, itching, sensations of burning,
swelling, dilatation or prominence of superﬁcial veins, and
skin changes. Signs may include telangiectasia, reticular
or varicose veins, edema, and skin changes such as pig-
mentation, lipodermatosclerosis, eczema, and ulceration. A
descriptive classiﬁcation, known as CEAP, was developed to
standardize reporting of chronic venous disorders (Table 1).
The CEAP classiﬁcation was based on clinical manifestations
(C), etiologic factors (E), anatomic distribution of disease
(A), and underlying pathophysiologic ﬁndings (P) [8, 9].
Because the history and physical examination are not
always able to determine the nature and extent of venous
insuﬃciency, a number of diagnostic investigations have
been developed [10]. Currently, duplex ultrasound is the
“gold standard” for venous imaging. Proper duplex ultra-
sound evaluation includes assessment of both reﬂux and
obstruction in the deep, superﬁcial, tributary, and perfo-
rating veins with precise mapping of abnormal pathways,
identiﬁcation of sources of reﬂux, accurate documentation
of all target vessels to be treated [11, 12]. In normal veins,
duplex examination reveals a cephalad ﬂow phasic with
respiration enhanced with distal thigh or calf compression.
Valve reﬂux is determined by the valve closure time, the time
taken for the valve to close after compression is released.
Duplex scanning shows that normal valvular closure time in2 International Journal of Vascular Medicine
Table 1: The CEAP classiﬁcation.
Clinical classiﬁcation (C)
C0 No visible or palpable signs of venous disease
C1 Telengiectases and/or reticular veins
C2 Varicose veins
C3 Edema
C4a Pigmentation and/or eczema
C4b Lipodermatosclerosis and/or atrophie blanche
C5 Healed ulcer
C6 Active ulcer
Cs
Symptoms, including ache, pain, tightness, skin
irritation, heaviness, muscle cramps
CA Asymptomatic
Etiologic classiﬁcation (E)
Ec Congenital (Klippel-Trenaunay syndrome)
Ep Primary
Es Secondary (post-thrombotic syndrome, trauma)
En No venous cause identiﬁed
Anatomic classiﬁcation (A)
As Superﬁcial
Ad Deep
Ap Perforator
An No venous location identiﬁed
Pathophysiologic classiﬁcation (P)
Pr Reﬂux
Po Obstruction, thrombosis
Pr,o Reﬂux and obstruction
Pn No venous pathophysiology identiﬁed
the standing position is less than 500ms in the superﬁcial
veins, deep femoral vein, and perforator veins while it is less
than 1000ms in the common femoral, femoral, and popliteal
veins. Reﬂux is considered to be present if the duration is
longer [13, 14].
Treatment of superﬁcial venous incompetence can be
accomplished by diﬀerent techniques including gradient
elastic compression stockings, ligation and stripping, scle-
rotherapy, ultrasound-guided sclerotherapy, endovenous
laser or radiofrequency thermal ablation, cutaneous lasers,
and intense pulse light devices [15, 16].
Varicose veins have a recurrence rate of 26% to 60% fol-
lowing surgery [17–19], making it important to understand
the pathophysiological mechanisms involved in the develop-
ment of varicose veins. Although varicose veins are relatively
common, the etiology and pathogenesis of primary varicose
veins remain unclear. Several proposals have been made to
explain the pathogenic mechanisms involved in this disease,
most notably are valvular incompetence and primary vein
wallchanges[20,21].Severalriskfactorshavebeenidentiﬁed
to contribute to the formation of varicose veins including
family history, age, sex, pregnancy, and prolonged-standing
occupations (orthostatism). Perturbations in hemodynamic
forces in the vein wall inﬂuence cytoskeletal organization,
gene expression, proliferation, and survival and may induce
inﬂammation and the subsequent remodeling of the wall
and venous valves. All these are fundamental mechanisms
thatunderlievariouspathologiesimplicatedinvaricoseveins
formation.
Because of the location of varicose veins in the lower
extremity, and the increase in lower extremity venous
pressure in the standing position, a relationship between
the lower extremity high venous pressure and the formation
of varicose veins has long been proposed. Nevertheless,
the molecular pathways responsible for the transduction
of the high venous pressure into vein wall dilation are
not clear. Speciﬁcally, how the venous pressure could be
trasduced to mechanical sensors in the vein wall, which in
turn aﬀect downstream signaling pathways and eventually
aﬀectmoleculartargetsthatmodulateveinfunction,remains
unclear. The purpose of this paper is to discuss some of
the reports in the Pubmed database in order to highlight
the role of mechanical transduction of venous hypertension
into biochemical pathways in the vein wall and their
eventual eﬀect on downstream target molecules. We will ﬁrst
discuss the physiological and pathological changes in lower
extremity venous pressure, the mechanosensors in the vein
wall, then the signaling mechanisms and vascular mediators
intheendothelium,venoussmoothmuscle,andextracellular
matrix of the venous wall. The discussion of these signaling
mechanisms and molecular targets would help in the design
of new molecular targets in the management and prevention
of recurrent varicose veins.
2. Orthostatic Venous Hypertension
In the upright position and in the absence of muscle
contraction, venous hydrostatic pressure measured on the
dorsum of the foot ranges from 90 to 120mmHg, depending
on the individual’s height [6]. Return of blood from the
dependent lower extremity to the heart requires overcoming
the eﬀects of hydrostatic pressure (the weight of the column
of blood below the right atrium), which is accomplished
by muscle pumps working in concert with venous valves.
When a normal subject exercises, the venous pressure re-
mains at a low and steady level throughout the period of
exercise [22]. However, the venous pressure measured in
insuﬃcient superﬁcial veins during walking fell to low levels
but still higher than those observed in normal veins and
returned to the preexisting levels much faster when walking
is stopped (Figure 1). These changes are attributed to the
reﬂux of blood distally during muscle relaxation with the
rapid establishment of the hydrostatic column and venous
hypertension. The observed pressure changes at the level of
the foot in normal veins are entirely dependent on intact and
functioning venous valves in the distal limb.
3. Mechanotransduction of
Venous Hypertension
Blood vessels are constantly subjected to various types of
hemodynamic forces including shear stress and circum-
ferential stretch induced by the blood ﬂow and pressure,International Journal of Vascular Medicine 3
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Figure 1: Diagram showing foot venous pressure during exercise
in the standing position. Lower curve illustrates normal venous
pressure while upper curve shows venous pressure in patients with
venous reﬂux.
respectively. Shear stress is the frictional force of the blood
on the endothelial layer while the circumferential stretch
is the circumferential distension of blood pressure [23].
These forces, shear stress on endothelial cells (ECs) and
circumferential stretch on ECs, medial smooth muscle
cells (SMCs), adventitial ﬁbroblasts (FBs), and extracellular
matrix (ECM), respectively, trigger and release biochemical
mediators that maintain physiological function of blood ves-
sels [23]. Multiple mechanosensors are involved in vascular
mechanotransduction [24]. While a plethora of knowledge
was gained from studies investigating mechanotransduc-
tion in arteries, little information is available regarding
mechanotransductioninveins.Becausevenoushypertension
is considered the primary underlying pathogenic mechanism
in varicose vein formation and because blood pressure is
translated into circumferential stretch on the vein wall, this
paper will discuss how circumferential stretch is sensed and
transduced in the vein wall.
4. Mechanotransduction of
CircumferentialStretch
Elevated venous pressure in the lower extremity veins during
prolonged standing generates circumferential stretch of the
vein wall and imposes mechanical stimulation on both
ECs and SMCs. Among the most studied mechanosensing
systems in response to circumferential stretch are the inte-
grins, the ﬂow-sensitive ion channels, and G protein coupled
receptors (GPCRs) (Figure 2)[ 25–28]. Other candidate
ﬂow sensors that have been proposed include the glyco-
calyx and the platelet endothelial cell adhesion molecule-
1/cadherin/vascular endothelial growth factor receptor-2
complex [23, 29–34].
5.Integrins
Integrins are a large family of cell surface receptors that
provide adhesion of cells to both the extracellular matrix
(ECM) and neighboring cells. The ability of integrins to
Table 2 :I n t e g r i n se x p r e s s e di nE C sa n dV S M C s .
ECs [39, 40] VSMCs [41, 42]
α1β1 α1β1
α2β1 α2β1
α3β1 α3β1
— α4β1
α5β1 α5β1
α6β1 α6β1
α6β4 α6β4
— α7β1
— α8β1
— α9β1
— αvβ1
αvβ3 αvβ3
αvβ5 αvβ5
act as a bridge between the extracellular environment and
cytoskeleton/signal protein kinases enables them to transmit
inside-out and outside-in signals and to mediate both
bidirectional force transmission and signal transduction via
an allosteric mechanism by switching between active and
inactive conformations [35, 36]. Each integrin receptor is a
noncovalently linked heterodimer composed of an α subunit
and a β subunit. There are at least 18 α subunits and 8 β
subunits, and these subunits associate to generate at least 24
diﬀerent integrins [37, 38]. Of the 24 known integrins, 16
have been reported to have involvement in some aspect of
vascular biology. Integrins reported to be expressed in ECs
and VSMCs are depicted in Table 2 [39–42].
Several studies have demonstrated the role of integrin as
mechanotransducers of circumferential stretch in ECs and
SMCs. Meng et al. studied the eﬀect of a single longitu-
dinal stretch on human saphenous vein and examined the
expression of integrin αv, matrix metalloproteinase (MMP)-
2 and pro-MMP-9, key molecules in vascular remodeling.
They found that, at peak expression on day 3, stretched
vein contained 206 ± 18% αv compared to nonstretched
veins. Stretched veins also secreted 177±16% active MMP-2
and 161 ± 36% pro-MMP-9 [43]. Several integrins such as
α2, α5, β1,a n dαvβ3 have been identiﬁed in SMCs derived
from human saphenous vein [44]. On the cellular level,
Sasamoto et al. demonstrated that mechanotransduction by
integrin is essential for IL-6 secretion from human umbilical
vein endothelial cells (HUVECs) in response to uniaxial
continuous stretch. The mechanical stretch activates integrin
which in turn activates NF-κB in a phosphatidylinositol 3-
kinase- (PI3-kinase-) dependent manner (Figure 2)[ 35].
The role of integrins as mechanotransducers has also
been reported in studies on cardiac and arterial SMCs.
In VSMCs from rat heart, cyclic strain was found to
stimulate mitogenesis through integrin αvβ3-dependent
release of platelet-derived growth factor [45]. In arterial
SMCs, integrin signaling is an integral element of the
response to the mechanical stress [23, 46]. Circumferential
stretch induces integrin activation through interactions with4 International Journal of Vascular Medicine
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Figure 2: Mechanosensors of circumferential stretch in ECs. Information is compiled for both arterial and venous ECs due to scarcity of
studies on venous ECs. Not all ion channels are included. This illustration is not drawn to scale.
the ECM [23, 47]. Downstream integrin signals to Rho
kinase and focal adhesion kinase (FAK) phosphorylation
pathways [23, 48]. Integrin activation is also involved in
Src-family tyrosine kinase activation by the direct protein-
protein interactions [49]. Activated Src kinase can further
activate FAK by phosphorylation. Paxillin is the target of
activated FAK for phosphorylation in addition to multiple
other kinases. The phosphorylated paxillin is involved in
coordinating the regulation of the cell’s motile machinery
a n dt h u si nc e l lm i g r a t i o na n ds u r v i v a l[ 50].
6.Flow-SensitiveIon Channels
Activation of ﬂow-sensitive ion channels is one of the most
rapidECresponsestoﬂow[25].Severaltypesofionchannels
in the ECs have been described including K+ channels, Ca2+-
activated K+ channels, Cl− channels, Ca2+ channels, and Na+
channels [24, 25, 51]. Flow-sensitive ion channels provide
ECs with the ability not only to sense ﬂow but also to
distinguish among and respond diﬀerently to diﬀerent types
of ﬂow [24]. The relevance of ﬂow-sensitive ion channels
in modulating EC susceptibility to inﬂammation induced by
low or oscillatory shear stress, a common ﬂow type in dilated
veins with functional reﬂux, is evident from the following
discussion. It has been shown that low and oscillatory
ﬂow are equally eﬀective in activating ﬂow-sensitive K+
channels, whereas Cl− channels are activated by steady ﬂow
but not oscillatory ﬂow [52]. In bovine aortic endothelial
cells (BAECs), pharmacological blockers of ﬂow-sensitive
K+ channels attenuate important endothelial responses to
ﬂow including release of both cGMP [53]a n dN O[ 54],
upregulation of transforming growth factor beta 1 (TGF-
β1)[ 55], and endothelial nitric oxide synthase (eNOS)
[56] mRNA levels, and downregulation of endothelin-1
protein expression (Figure 2)[ 25, 57]. Several studies have
demonstrated the involvement of ion channels in venous
dilatation and varicose vein formation. Raﬀetto et al. showed
thatMMP-2causedrelaxationofratinferiorvenacava(IVC)
circular segment by activation of two types of K+ channels,
the ATP-sensitive K+ channel (KATP)a n dl a r g ec o n d u c t a n c e
Ca2+-activated K+ channel (BKCa)[ 58]. Recently, Xia et al.
s h o w e di nr a tI V Car e d u c e dC a 2+ entry via voltage-gated
Ca2+ channels in female compared with male. In this study
the authors found that the reduced contraction, Ca2+,a n d
Ca2+ sensitivity in female veins render them more prone to
dilation. These sex-speciﬁc reductions in venous function,
if they also proved to occur in human veins, may explain
the greater incidence of varicose veins in females [59].
Although these studies demonstrate that ion channels could
be involved in varicose vein formation, their activation wasInternational Journal of Vascular Medicine 5
not ﬂow-mediated and thereby cannot be considered due to
mechanotransduction of venous pressure.
7.GProtein-CoupledReceptors(GPCRs)
IthasbeenshownthatangiotensinIItype1receptor(AT1R),
a member of the GPCR family, is widely expressed in the
vasculature. Although the following discussion is based on
experimental studies of GPCR in arteries, the existence
of myogenic response in human saphenous veins and the
recent discovery of involvement of GPCR in this physiologic
response (see below) would support a possible link between
GPCR as a mechanotransducer and varicose vein develop-
ment. This assumption needs to be proved by future studies.
AT1R can be activated directly by circumferential stretch in
the absence of a ligand, that is, independent of angiotensin
II [60], leading to an active AT1R receptor conformation
[61]. AT1R activation induces vascular constriction and
upregulates NADPH oxidase activity and enhances super-
oxide production resulting in ECs and SMCs dysfunction.
The increase in superoxide production by vascular cells
caused by stretch has been implicated in activation of
NFκB[ 62], activation of MMPs [63], MAP kinase activation
[64], angiogenesis [65], and altered vasomotion [66]. The
downstream signals from AT1R include Rac activation via
PI3-kinase activation (Figure 2)[ 23, 67].
Another mechanism by which GPCRs act as mechano-
sensors is in cooperation with transient receptor potential
ion channels (TRPCs). Schnitzler et al. show that GPCRs,
including AT1R, are essential mechanosensing components
inVSMCsandfunctionassensorsofmembranestretchlead-
ingtoTRPCactivation[26].Stretchinducesactivationofthe
trimeric G proteins. The activated GPCRs lead to activation
of phospholipase C (PLC), which hydrolyses the membrane
phospholipidsphosphatidylinositol4,5-bisphosphate(PIP2)
into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate
(IP3). TRPC channels have been shown to be activated by
PLC [68], possibly through direct actions of DAG [69, 70]
generatedthroughPLCactivity[26].TRPCactivationresults
in Ca2+ inﬂux and smooth muscle contraction (Figure 2)
[71]. Although these pathways were reported in cerebral
and renal arteries, the same or similar paradigm may be
operativeinveinsexhibitingmyogenicresponse.Studieshave
shown that saphenous vein of humans and animals exhibits
an active myogenic response with vasoconstriction when
subjected to increased intraluminal pressure [72, 73]. It is
plausibletospeculatethatdysfunctionoftheAT1R-mediated
activation of TRPC would lead to loss of the myogenic
response (vein wall vasoconstriction) to the high venous
pressure with subsequent vein wall dilation.
8.StretchSignalingPathwaysinVaricose Veins
Although the link between mechanosensors translation of
circumferential stretch to biological molecules remains to
be fully elucidated, considerable knowledge of downstream
signaling pathways has been gained. The multitude of
signaling pathways involved in varicose vein formation can,
however, be grouped under three mechanisms, vein wall
hypoxia, inﬂammation, and remodeling (Figure 3).
8.1. Stretch-Induced Hypoxia . Hypoxia of the lower extrem-
ity vein wall has been proposed as a causative factor in
varicose vein formation [74–76]. Oxygen and nutrients
are supplied by diﬀusion from the vein lumen to the
endothelial and inner third of the media and from vasa
vasorum to the outer two-thirds of the media [74, 77].
Venous hypertension and blood stasis both contribute to
hypoxia of the varicose vein wall. Endoluminal hypoxia
due to stagnation of venous blood ﬂow results in reduced
oxygen replenishment in comparison to normal venous ﬂow.
Endothelial and inner layers of the vein wall are mainly
aﬀected by endoluminal hypoxia [78]. Distension of the
vein by hydrostatic pressure secondary to blood stasis causes
compressionofvasavasorumleadingtohypoxiaofthemedia
and outer layers of the vein wall [79].
Several studies have measured the oxygen content of
venous blood carried in varicose and nonvaricose veins.
Unfortunately, the ﬁndings from these studies have been
inconsistent and inconclusive due to variation of sampling
(site, posture, type of control vein) and method of oxygen
measurement [74]. On the other hand, only one study
measured and compared vein wall oxygen tension between
varicose and non-varicose veins in vivo. In this study, the
authors reported that the average minimum oxygen tensions
were signiﬁcantly lower in the media of varicose compared
to non-varicose veins (7.9 versus 13.4mmHg; P<0.05)
[76]. Taken together, it can be concluded that several factors
act synergistically to accentuate vein wall hypoxia. Venous
hypertension produces stretch of the vein wall which causes
increased vein wall oxygen demand and compression of
vasa vasorum; both lead to vein wall hypoxia. Vein wall
h yp o x i ai nt u r nl e a d st ov e i nr e l a x a t i o n[ 80] leading to blood
stasis, which accentuates venous hypertension, and increased
vein wall tension, and so on. This self-perpetuating cycle
continues as long as venous hypertension is maintained [74].
As hypoxia of the wall of the vein continues the number
of vasa vasora should also increase in number in order
to provide nutrition and oxygen to the dilated hypoxic
vein wall. Histological examinations of varicose veins have
consistently demonstrated an increase in the number of vasa
vasorum in the wall of varicose veins particularly in the
hypertrophic portions in comparison to the atrophic por-
tions of varicose veins or to normal veins [81, 82]. It is well
known that the proangiogenic cytokine, vascular endothelial
growth factor (VEGF), and its upstream transcription factor
hypoxiainduciblefactor-1alpha(HIF-1α)playanimportant
role in new vessel formation such as vasa vasora (Figure 3)
[83, 84] .T h er o l eo fV E G Fi nv a r i c o s ev e i n sw a sr e p o r t e d
in several publications. It has been demonstrated that both
VEGFproteinandreceptorandthetranscription factorHIF-
1α are elevated in the wall of varicose veins in comparison
with normal veins [85, 86]. The plasma levels of VEGF
have been shown to increase during the venous hypertension
induced by 30min of standing in both normal subjects and
patients with varicose veins. Both supine and standing VEGF6 International Journal of Vascular Medicine
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Figure 3: Signaling pathways of varicose vein formation.
levels are higher in patients than in normal controls [87].
Moreover, plasma VEGF levels are higher in varicose vein
patients with skin changes than in varicose vein patients
with normal skin [88]. Finally, Howlader and Coleridge
measured plasma levels VEGF using ELISA in 108 patients
with varicose veins of diﬀerent clinical stages and in 30
volunteers in order to determine basal VEGF levels and to
explore the relationship between symptoms attributable to
venous disease and VEGF. The study showed that there was a
trend towards raised VEGF in all stages of varicose veins, but
this only reached statistical signiﬁcance in those with healed
ulceration. The symptom of swelling was associated with
raised VEGF levels; however, the symptoms of heaviness,
cramps, and paresthesias were not associated with raised
VEGF levels [89].
Several animal studies supported the role of stretch-
induced HIF/VEGF in the increase of vasa vasorum in the
wall of varicose veins. Milkiewicz et al. found that HIF-
1α and HIF-2α were elevated in stretch-induced but not
shear-stress-induced angiogenesis. Rat extensor digitorum
longus muscles were overloaded to induce stretch or exposed
to the dilator prazosin to elevate capillary shear stress,
and capillaries from these muscles were isolated by laser
capture microdissection for RNA analysis. HIF-1α and HIF-
2α transcript levels increased after 4 and 7 days of stretch,
whereas a transient early induction of HIF-1α and HIF-
2α transcripts was detected in capillaries from prazosin-
treated muscles. Skeletal muscle microvascular endothelial
cells exposed to 10% stretch in vitro showed an elevation in
HIF-1αandHIF-2αmRNA, which was preceded by increases
in HIF-binding activity. Conversely, HIF-1α and HIF-2α
mRNAs were reduced signiﬁcantly, and HIF-α proteins
were undetectable, after 24h exposure to elevated shear
stress. Together, these results illustrate that activation of
HIF-1α and HIF-2α contributes signiﬁcantly to stretch-
but not to shear-stress-induced angiogenesis [90]. Recently,
Lim et al. reported that HIF-1α and HIF-2α mRNA were
o v e r e x p r e s s e di ns e g m e n t so fr a tI V Ce x p o s e dt op r o l o n g e d
2-g tension and that the overexpression was reversed by the
HIF inhibitor U0126 [91]. Therefore, from the above clinicalInternational Journal of Vascular Medicine 7
and experimental studies one can speculate that distention
of the vein by the elevated hydrostatic pressure secondary
to venous stasis causes compression of vasa vasorum leading
to vein wall hypoxia. Vein wall hypoxia and stretch induce
upregulation of HIF-1 expression. HIF-1 causes elevation
of VEGF, MMP-2 and MMP-9 expression. VEGF stimu-
lates angiogenesis and the increase in the number of vasa
vasorum. MMP-2 and MMP-9 degrade collagen 3, produce
vein dilation, and activate of TGF-β.T G F - β activates genes
responsible for tissue remodeling such as connective tissue
growth factor (CTGF) leading to increased collagen 1 and
ﬁbronectin production.
8.2. Stretch-Induced Inﬂammation. Evidence has accumu-
lated to support the role of venous hypertension and shear
stress in the development of inﬂammation both of the
wall of the veins and in the surrounding dermal and
subdermal tissues [92]. It is generally agreed that laminar
shear stress promotes the release of factors that suppress
inﬂammation and reactive free radicals production, while
low shear stress, turbulent ﬂow, and stasis promote the
production of inﬂammation and thrombosis [4]. Although
it is not known what initiates the inﬂammatory events in the
vein wall, it is generally accepted that leucocyte-endothelial
interaction is the underlying mechanism. ECs are activated
by hypoxia or by altered shear stress [78]. Leucocytes are
alsoactivatedbyalteredshearstressandvenoushypertension
[93, 94]. Studies have shown that the plasma markers
of leucocyte activation and leucocyte-endothelial interac-
tion (L-selectin, intercellular adhesion molecule (ICAM)-
1, endothelial leukocyte-adhesion molecule (ELAM)-1,
vascular-cell adhesion molecule (VCAM)-1 are increased
after subjecting patients with varicose veins to 30 minutes of
standing to induce venous hypertension (Figure 3)[ 94, 95].
Also plasma from patients with varicose veins induces more
oxygen free radical production and pseudopod formation
in normal, quiescent leukocytes indicating their activation
than does plasma from control subjects [96]. Neutrophil
leucocyte activation was also demonstrated by the ﬁnding
thatplasmafrompatientswithvaricoseveinscontainshigher
levels of lactoferrin and neutrophil elastase than in age- and
sex-matched controls. These enzymes are released from neu-
trophil granules and are considered markers of neutrophil
activation [97]. In addition, monocytes/macrophages, lym-
phocytes, and mast cells have all been detected in the wall
as well as valves of varicose veins [98, 99]. Moreover, it was
demonstrated that activation was restricted not only to the
luminal venous endothelium but also the endothelium in
the vasa vasora of reﬂuxing saphenous veins, as indicated
by the upregulation of ICAM-1 [100]. A recent study has
reported the expression of proinﬂammatory cytokines and
chemokines in patients with varicose veins. This study found
a marked expression of monocyte-chemoattractant pro-
tein (MCP)-1, macrophage-inﬂammatory protein (MIP)-
1α,M I P - 1 β, interferon-γ-inducible protein (IP)-10, inter-
leukin (IL)-8, and RANTES in varicose veins, suggesting
that chemokines might play an important role in their
pathophysiology byrecruiting leucocytes to the vein walland
contributing to inﬂammation and edema. It is known that
MCP-1,MIP-1α,MIP -1β,andIP-10arechemoattractantsfor
monocytes/macrophages, IL-8 is able to attract neutrophils,
and RANTES is a chemotactic molecule for leucocytes [101].
Taken together, there is ample evidence of a role of inﬂam-
mation in varicose vein formation and that inﬂammation is
produced at least in part by venous hypertension. It remains,
however, to delineate the molecular mechanism by which
venous hypertension produces inﬂammation and whether
this mechanism involves mechanotransduction of the altered
shear stress and circumferential stretch operative in varicose
veins.
Superoxide production has been shown to contribute
to vein wall inﬂammation and dysfunction. It has been
shown that sustained stretch increases O−2 production by
both cultured ECs and SMCs [62, 102]. Stretch results
in angiotensin II (Ang II) release from the ECs which
acts on AT1R to enhance the activity of NADPH oxidase
leading to higher superoxide production [23, 103]. Super-
oxide scavenges nitric oxide (NO) and therefore abolishes
i t sv a s o p r o t e c t i v ee ﬀects [23]. Thus increased stretch and
its subsequent stimulation of vascular oxidant stress may
contribute to the cellular dysfunction encountered in the
wall of varicose veins (Figure 3)[ 62]. Interestingly, Sohn et
al. demonstrated that Ang II was shown to activate Ang II
receptor type 2 (AT2R) which antagonizes AT1R-mediated
superoxide formation in endothelial cells by a pathway
involving tyrosine phosphatases [104]. Additionally, AT2R
enhances eNOS phosphorylation via bradykinin receptors
and elevates NO generation [105]. The relative distribution
of both receptor subtypes on the same cell type, which
may vary following prolonged venous hypertension, may
therefore inﬂuence endothelial superoxide formation and
hence NO dependent dilation.
8.3. Stretch-Induced Vein Wall Remodeling
8.3.1. Role of Collagen and Elastin. Several studies demon-
strated that there is signiﬁcant hypertrophy of the media
layer of the wall of varicose veins compared with normal
veins [106]. Other studies showed that the medial layer
consisted of increased number of collagen ﬁbres and that
elastin ﬁbres are constantly fragmented with paralleled
interruption of the internal elastic lamina. The adventitial
layer showed decreased density and size of elastin ﬁbres and
increasedﬁbredegradation[107,108].Severalofthechanges
observedinconnectivetissuearethoughttoreﬂectvariations
in the levels of MMPs, the enzymes involved in regulat-
ing and maintaining the extracellular matrix that degrade
extracellular matrix molecules, proteoglycans, elastin, and
diﬀerent types of collagens [109].
Biochemical studies have also demonstrated a decrease
in the elastin content of the aﬀected vein wall [110]. Pascual
et al. recently demonstrated that the reduction in elastin in
the varicose condition may be related to the decreased lysyl
oxidase-like 1 (LOXL1) levels observed. LOXL1 is a cross-
linking enzyme responsible for elastin polymer deposition.
Theseeventscouldreducespontaneousreticulationofelastin
andthepartiallossoftissueelasticityinthisgroupofpatients
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Collagen dysregulation in varicose veins have also been
the subject of several studies. Collagen type I mRNA
expression and protein synthesis are increased in tissue
media of varicose veins due to gene overexpression [112,
113]. Collagen III production in SMCs from varicose veins,
however, was shown to be decreased due to extracellular
degradation by a mechanism involving MMPs (Figure 3)
[114]. This imbalance between the synthesis of collagen type
I and collagen type III could explain the lack of elasticity of
varicose veins [112].
In a recent investigation that examined the link between
the loss of ECM and the biophysical properties of varicose
veins, Jeanneret and colleagues identiﬁed that adventitial
elastin and intimal type III collagen were speciﬁcally and
diﬀerentially aﬀected. The selective loss of these two elastic
structural proteins can explain two biophysical properties of
the vein wall. Venous adventitial elastin has a critical role in
regulating the venous diameter at rest, and, therefore, elastin
loss may be a key factor in the development of varicose veins,
preceding and precipitating dilatation. The concomitant
reductioninintimaltypeIIIcollagenisinvolvedinabnormal
distensibility [115].
8.3.2. Role of MMPs. The relation between venous stretch
and MMP expression in the wall of varicose veins has been
extensively investigated. In a series of studies to clarify the
relationship between MMP and vein wall dilatation, Raﬀetto
et al. showed that MMPs exert vasoactive eﬀect on vein
wall. They demonstrated that MMP-2 (1mg/mL) caused
relaxation of phenylephrine-contracted rat IVC segments by
a mechanism involving hyperpolarization and activation of
K+ channels [58]. Another study from the same group was
performed in rat IVC to test the hypothesis that prolonged
increases in vein wall tension cause overexpression of
MMPs and decreased contractility, which in turn promotes
venous dilation. The results demonstrated that increases in
magnitude and duration of wall tension were associated
with reduced contraction and overexpression of MMP-2
and MMP-9. There was a direct correlation between the
expression of MMP-2 and MMP-9 and decreased vein
contractile function [116]. More recently, they reported the
results of a study evaluating rat IVC stretch in the induction
ofHIFandMMPs.ThemainstudyﬁndingswerethatHIF-1α
and HIF-2α mRNAs were overexpressed in IVC exposed to
prolonged 2-g tension, and the overexpression was reversed
by the inhibitors of HIF. In addition, the overexpression
of HIF-1α and HIF-2α in stretched IVC was associated
with increased MMP-2 and MMP-9 mRNAs and proteins.
The authors concluded that prolonged increases in vein
wall tension are associated with overexpression of HIF-1α
and HIF-2α, increased MMP-2 and MMP-9 expression, and
reduced venous contraction in rat IVC. This study elucidated
the mechanism and relation of HIFs and MMPs indicating
that increased vein wall tension induces HIFs overexpression
and causes an increase in MMPs expression and reduction
of venous contraction, leading to progressive venous dilation
which may contribute to varicose vein formation (Figure 3)
[91].
8.3.3. Role of TGF-β1. Several studies have demonstrated
that mechanical stretch can activate latent TGF-β1 present in
the ECM and that this process is inhibited by antagonizing
integrins and independent from protease activity, thus
establishing a link between the mechanical force of vein
wall stretch and activation of the biological molecule, TGF-
β1 [117–120]. TGF-β1 is a multifunctional cytokine that
regulates diverse cellular functions such as proliferation,
migration, diﬀerentiation, and extracellular matrix produc-
tion.
Clinical investigations have demonstrated increased
expression of TGF-β1 and its downstream signaling proteins
in the wall of varicose veins compared to normal veins
(Figure 3)[ 82, 121, 122]. Jacob et al. investigated the
expression and correlation of TGF-β1 and loss of vascular
SMCs, in a series of normal and varicose vein specimens.
They found that TGF-β1 was diﬀerentially overexpressed
in varicose veins with greater expression in the tortuous
segments compared with the nontortuous segments of the
varicose vein. Only a very small amount of expression of
TGF-β1 w a sd e t e c t e di nn o r m a lv e i ns a m p l e s .H i s t o l o g i c a l
examination revealed disruption of elastic lamellae and a
signiﬁcantly high degree of loss of vascular SMCs [81]. It has
been shown that TGF-β1 acts as a bifunctional regulator of
SMCproliferation,apoptosis,migration,andphenotype[81,
123]. O’Callaghan and Williams have shown that exposing
human SMCs cells to 5 days of chronic cyclical mechanical
strain increased ﬁbronectin and collagen concentrations and
MMP-2activityandTGF-β1 expressionwhencomparedwith
cells grown in static conditions [124].
These studies showed that mechanical stress is respon-
sible for overexpression of TGF-β1 and for activation of its
latent inactive form that already exist in the ECM. Moreover,
it has also been demonstrated that TGF-β1 mediates tissue
remodeling through regulation of collagen synthesis, MMP
synthesis, and diﬀerentiation of ﬁbroblasts into contractile
myoﬁbroblasts.
9. Conclusions and Perspectives
The pathobiology of varicose vein formation is one of
the ﬁelds that need increasing research attention given
the signiﬁcant social, medical, and economic importance.
The recent characterization of several mechanosensors in
the ECs and SMCs will stimulate future research of the
mechanotransduction signaling pathways involved in the
development of varicose veins. Possible areas of future
research and intervention could be suggested based on
current understanding of mechanotransduction. One such
research areas would investigate stretch-induced myogenic
response in human saphenous vein. Given that studies have
shown that saphenous vein of humans and animals exhibits
an active myogenic response and that stretch-induced AT1R
and TRPC channels signaling mechanism are responsible
for the myogenic response in arteries, it remains, however,
to delineate the underlying signaling pathways and the
identity of mechanosensors of myogenic response in human
superﬁcial veins of the lower extremities. Failure of thisInternational Journal of Vascular Medicine 9
myogenic response may have a critical role in the devel-
opment of varicose veins. A second area of research would
be conﬁrming in nonvaricose and varicose saphenous veins
the previous animal studies that shows reduced contraction
in female rat IVC compared with male due to reduced
Ca2+ entry via voltage-gated Ca2+ channels. This would
explain the greater incidence of varicose veins in females.
A third topic would be investigating the relevance of ﬂow-
sensitive ion channels, such as ﬂow-sensitive K+ channels,
in modulating venous ECs susceptibility to inﬂammation
induced by low or oscillatory shear stress in human varicose
veins. Future studies should also conﬁrm and expand on
previous ﬁndings showing that a single longitudinal stretch
of saphenous vein grafts produces signiﬁcant increase in the
expression and activation of αv integrin, MMP-2, and MMP-
9, key molecules in vascular remodeling. These and other
studies would expand our understanding on how vein wall
ECs, SMCs, FBs, and ECM sense and transduce stimuli of
hemodynamic forces, particularly venous hypertension, into
biochemical signals. This knowledge would be critical to
developing new therapies for the prevention and treatment
of varicose veins.
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